Skip to main content

Wound healing ILYA-style 2

Project description

Proprietary dressings for the treatment of chronic wounds

Treatment of non-healing chronic wounds represents an unmet clinical need with conventional wound dressings failing to protect against recurrent infections, leading to increased mortality. The rising incidence of diabetes and obesity alongside antibiotic resistance exacerbate the situation. The EU-funded WHILYAS-2 project proposes to address the insufficient treatment of chronic wounds through a proprietary technology that utilises chemokines as therapeutic agents through local administration from genetically modified lactic acid bacteria. For clinical proof of concept, partners will conduct a phase II clinical trial of their drug candidate ILP100 Topical in patients with diabetes.

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Coordinator

ILYA PHARMA AB
Address
Dag Hammarskiolds Vag 30
752 37 Uppsala
Sweden

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 360 362